HealthDaily digest, November 12, 2026
AI's Promise and Payoff in Healthcare
This week in AI healthcare, Google DeepMind unveiled a more precise genetic analysis tool, while new research questions whether AI investments actually save hospitals money. The stories highlight both the technological advances and the practical challenges healthcare systems face when adopting AI.
Google DeepMind's AlphaGenome 2 Analyzes Genes at Single-Cell Level
Google DeepMind has released AlphaGenome 2, an upgraded AI model that examines genetic variants in individual cells rather than entire tissue samples, trained on over 107 million cell profiles. The system identifies roughly twice as many disease-relevant gene changes as the original version, potentially accelerating disease research and helping scientists design better treatments tailored to specific cell types.
Why it matters: More precise genetic analysis could accelerate understanding of disease mechanisms and improve drug discovery, potentially leading to better treatments tailored to specific cell types.
Sources: The Decoder
Study Finds AI Care Plans May Cost Hospitals More, Not Less
A study published in the New England Journal of Medicine discovered that AI-generated care plans can cost significantly more than those created by doctors, contradicting the expectation that AI would reduce healthcare expenses. As hospitals invest heavily in AI to improve their operations, administrators now face uncertainty about whether these tools will deliver promised financial savings.
Why it matters: Hospital administrators considering AI investments need to understand that AI tools may increase rather than decrease costs despite claims of efficiency gains.
Sources: MedCity News